Schizophrenia is an often disabling psychiatric disease that usually requires long-term treatment. The primary goals of medical treatment for schizophrenia are to reduce the frequency and severity of psychotic episodes, maintain the reduction in these symptoms over the long term, and improve patients’ functional capacity. Antipsychotics are the cornerstone of schizophrenia treatment, with the crowded atypical and typical antipsychotic drug classes resulting in a complex treatment algorithm. Given the genericization of key oral therapies and the availability of newer oral and long-acting depot antipsychotics in the United States, such as Indivior’s Perseris, Otsuka / Lundbeck’s Rexulti, Allergan’s Vraylar, and Alkermes’s Aristada, competition in the U.S. market continues to intensify. As such, an understanding of the nuanced schizophrenia treatment landscape is essential to assess remaining opportunities for drugs in the space.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed schizophrenia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed schizophrenia patients?
- How have newer agents such as Perseris, Rexulti, Vraylar, and Aristada been integrated into the treatment algorithm, and what is their source of business?
- What percentage of schizophrenia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of schizophrenia patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States.
Real-world data: Longitudinal patient-level claims data analysis.
Key drugs covered: Abilify Maintena, Aristada, Invega Sustenna, Invega Trinza, Latuda, Rexulti, Risperdal Consta, Vraylar, Perseris, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, typical antipsychotics, other generics.
Key analysis provided:
- Brand/therapy usage across a longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowchart.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Schizophrenia - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms CDA-Schizophrenia-US-April 2020
Author(s): Shefali Gulati, MBA Pharm
Shefali Gulati, Associate analyst, is part of the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group.
She is responsible for performing extensive secondary market research and analysis for major pharmaceutical markets. She comes with one year of experience working on multiple client projects revolving around opportunity assessment, competitive landscape, pipeline analysis, and key product profiling. She holds a MBA degree in Pharmaceutical Management from the National Institute of Pharmaceutical Education and Research (NIPER) in India and Bachelor’s in Pharmacy from DIPSAR.